Iterum Therapeutics (ITRM) Price & Analysis

Compare

924 Followers

ITRM Stock Chart & Stats

$0.47

-$0.04(-2.14%)

At close: Jan 08 4:00 PM EST

$0.47

-$0.04(-2.14%)

Day’s Range― - ―

52-Week Range$0.36 - $3.02

Previous CloseN/A

Volume220.96K

Average Volume (3M)813.22K

Market Cap

$29.40M

Enterprise Value$59.27M

Total Cash (Recent Filing)$11.00M

Total Debt (Recent Filing)$33.73M

Price to Earnings (P/E)―

Beta1.64

Next Earnings

Mar 12, 2026

EPS Estimate

-0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.16

Shares Outstanding48,051,160

10 Day Avg. Volume1,119,323

30 Day Avg. Volume813,222

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)-8.54

Price to Sales (P/S)0.00

P/FCF Ratio-1.30

Enterprise Value/Market Cap2.02

Enterprise Value/Revenue151.97

Enterprise Value/Gross Profit-88.72

Enterprise Value/Ebitda-2.57

Forecast

1Y Price Target

$2.00

Price Target Upside325.53% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Market OpportunityORLYNVAH targets uncomplicated urinary tract infections (uUTI) with exclusivity in the US until 2034, creating a significant market opportunity for Iterum.

Revenue GrowthThe expectation remains that ORLYNVAH revenue should grow, slowly at first and then over time begin to ramp given increased awareness that an oral penem is available in the US for uUTIs.

Strategic PartnershipsIterum's strategic and targeted approach in launching ORLYNVAH is supported by partnerships with Eversana and Alto Specialty Pharmacy, which enhances their sales and logistics capabilities.

Bears Say

CompetitionThe presence of competing products from companies like GSK in the uUTI market may influence Iterum's stock performance, although ORLYNVAH remains a more attractive therapeutic option.

Coverage Expansion ChallengesThis is going to take some time to build traction and payer coverage expansion, which is at 16% covered lives, needs to expand.

Price Target ReductionGiven commercial sales risk and capital constraints, combined, this lowers the price target to $2.00, from $5.00.

Iterum Therapeutics News

Iterum Therapeutics says ORLYNVAH access ‘continues to grow’

The company said, “Market Access Update: Expanding Reimbursement Footprint: ORLYNVAH’s access continues to grow-both with and without prior...

2d ago

ITRM

Iterum Therapeutics receives 510(k) clearance for Susceptibility Test Disc

Iterum Therapeutics (ITRM) provided a business update. Specialty Distributor Now Stocked: ORLYNVAH is now available at McKesson, which...

13d ago

ITRM

Iterum Therapeutics sees cash runway into 2Q26

Cash and cash equivalents were $11.0 million as of September 30, 2025. Based on Iterum’s current operating plan,...

23d ago

ITRM

Iterum Therapeutics sees FY26 ORLYNVAH net product sales $5M-$15M

07:07 EST Iterum Therapeutics (ITRM) sees FY26 ORLYNVAH net product sales $5M-$15M Published first on TheFly – the...

23d ago

ITRM

Iterum Therapeutics reports Q3 non-GAAP EPS (16c) vs. (24c) last year

Reports Q3 revenue $390,000 vs. $0 last year. “We are thrilled to have launched ORLYNVAH in the United...

23d ago

ITRM

Buy Rating Maintained for Iterum Therapeutics Despite Initial Challenges, Driven by Unique Market Position of ORLYNVAH

Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Iterum Therapeutics and decreased the price target...

18d ago

ITRM

Iterum Therapeutics Reports Q3 2025 Financial Results

Iterum Therapeutics ( ($ITRM) ) has released its Q3 earnings. Here is a breakdown of the information Iterum...

22d ago

ITRM

Iterum Therapeutics’ Earnings Call: Optimism Amid Challenges

Iterum Therapeutics (($ITRM)) has held its Q3 earnings call. Read on for the main highlights of the call....

22d ago

ITRM

Is ITRM a Buy, Before Earnings?

Iterum Therapeutics (ITRM) is scheduled to report 3rd quarter earnings on 11/07/2025. Regarding Q3 estimates, Wall Street analysts...

1M ago

ITRM

Iterum Therapeutics Advances Adolescent Antibiotic Trial: Key Insights for Investors

Iterum Therapeutics (($ITRM)) announced an update on their ongoing clinical study. Iterum Therapeutics is launching a Phase 1...

1M ago

ITRM

Iterum Therapeutics Announces $20M Share Offering

Iterum Therapeutics ( ($ITRM) ) has issued an update. On October 16, 2025, Iterum Therapeutics announced a prospectus...

2M ago

ITRM

Iterum Therapeutics sees cash runway into 2026

Iterum Therapeutics (ITRM) provided a general business update. ORLYNVAH Launch Update: In partnership with EVERSANA Life Science Services,...

3M ago

ITRM

Iterum Therapeutics Faces Shareholder Pushback on Key Proposals

Iterum Therapeutics ( ($ITRM) ) has provided an update. On September 10, 2025, Iterum Therapeutics held its annual...

3M ago

ITRM

Iterum Therapeutics Faces Nasdaq Delisting Notice

The latest update is out from Iterum Therapeutics ( ($ITRM) ). On August 25, 2025, Iterum Therapeutics plc...

3M ago

ITRM

ITRM FAQ

What was Iterum Therapeutics Plc’s price range in the past 12 months?

Iterum Therapeutics Plc lowest stock price was $0.36 and its highest was $3.02 in the past 12 months.

What is Iterum Therapeutics Plc’s market cap?

Iterum Therapeutics Plc’s market cap is $29.40M.

When is Iterum Therapeutics Plc’s upcoming earnings report date?

Iterum Therapeutics Plc’s upcoming earnings report date is Mar 12, 2026 which is in 95 days.

How were Iterum Therapeutics Plc’s earnings last quarter?

Iterum Therapeutics Plc released its earnings results on Nov 14, 2025. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.09 by -$0.07.

Is Iterum Therapeutics Plc overvalued?

According to Wall Street analysts Iterum Therapeutics Plc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Iterum Therapeutics Plc pay dividends?

Iterum Therapeutics Plc does not currently pay dividends.

What is Iterum Therapeutics Plc’s EPS estimate?

Iterum Therapeutics Plc’s EPS estimate is -0.15.

How many shares outstanding does Iterum Therapeutics Plc have?

Iterum Therapeutics Plc has 48,051,160 shares outstanding.

What happened to Iterum Therapeutics Plc’s price movement after its last earnings report?

Iterum Therapeutics Plc reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.09. Following the earnings report the stock price went down -16.071%.

Which hedge fund is a major shareholder of Iterum Therapeutics Plc?

Currently, no hedge funds are holding shares in ITRM

Company Description

Iterum Therapeutics Plc

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Iterum Therapeutics (ITRM) Earnings & Revenues

Historic Earnings Reports

ITRM Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted the successful early stages of Orlynda's launch and positive market feedback, indicating potential for growth. However, financial challenges remain due to limited initial revenue, increased expenses, and the need for additional capital.View all ITRM earnings summaries

ITRM Stock 12 Month Forecast

Average Price Target

$2.00

▲(325.53% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"Jun<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.67,0.7723076923076924,0.8746153846153847,0.976923076923077,1.0792307692307692,1.1815384615384614,1.2838461538461539,1.3861538461538463,1.4884615384615385,1.5907692307692307,1.693076923076923,1.7953846153846156,1.8976923076923078,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.67,0.7723076923076924,0.8746153846153847,0.976923076923077,1.0792307692307692,1.1815384615384614,1.2838461538461539,1.3861538461538463,1.4884615384615385,1.5907692307692307,1.693076923076923,1.7953846153846156,1.8976923076923078,{"y":2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.67,0.7723076923076924,0.8746153846153847,0.976923076923077,1.0792307692307692,1.1815384615384614,1.2838461538461539,1.3861538461538463,1.4884615384615385,1.5907692307692307,1.693076923076923,1.7953846153846156,1.8976923076923078,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.17,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.22,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.77,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.6,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.17,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.73,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.67,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.67,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >